BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO • US0905722072
255.39 USD
-1.17 (-0.46%)
Last: Feb 17, 2026, 10:37 AM
We assign a fundamental rating of 4 out of 10 to BIO. BIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year BIO was profitable.
- BIO had a positive operating cash flow in the past year.
- In the past 5 years BIO reported 4 times negative net income.
- Of the past 5 years BIO 4 years had a positive operating cash flow.
1.2 Ratios
- BIO's Return On Assets of -6.97% is in line compared to the rest of the industry. BIO outperforms 53.45% of its industry peers.
- The Return On Equity of BIO (-10.03%) is comparable to the rest of the industry.
- BIO's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. BIO outperforms 63.79% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 12.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- Looking at the Operating Margin, with a value of 10.27%, BIO is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
- In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
- BIO has a better Gross Margin (52.42%) than 63.79% of its industry peers.
- In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
- There is no outstanding debt for BIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 3.12 indicates that BIO is not in any danger for bankruptcy at the moment.
- BIO has a Altman-Z score of 3.12. This is in the better half of the industry: BIO outperforms 72.41% of its industry peers.
- BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
- BIO's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO outperforms 77.59% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.18, BIO perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.12 |
ROIC/WACC0.22
WACC10.47%
2.3 Liquidity
- BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- BIO has a Current ratio of 5.44. This is amongst the best in the industry. BIO outperforms 86.21% of its industry peers.
- BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 3.94, BIO is doing good in the industry, outperforming 68.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO have decreased by -3.78% in the last year.
- The Earnings Per Share has been decreasing by -1.19% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
3.2 Future
- BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.38% yearly.
- BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.60% yearly.
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 25.74, BIO can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, BIO is valued a bit cheaper than the industry average as 68.97% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.19. BIO is around the same levels.
- Based on the Price/Forward Earnings ratio of 24.91, the valuation of BIO can be described as rather expensive.
- Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 72.41% of the companies in the same industry.
- BIO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.74 | ||
| Fwd PE | 24.91 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 82.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.46 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- A cheap valuation may be justified as BIO's earnings are expected to decrease with -3.38% in the coming years.
PEG (NY)7.72
PEG (5Y)N/A
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
5. Dividend
5.1 Amount
- No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BIO (2/17/2026, 10:37:06 AM)
255.39
-1.17 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners92.92%
Inst Owner Change1.78%
Ins Owners8.18%
Ins Owner Change0%
Market Cap6.89B
Revenue(TTM)N/A
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (41.78%)
Short Float %4.47%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-4.14%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.74 | ||
| Fwd PE | 24.91 | ||
| P/S | 2.69 | ||
| P/FCF | 20.46 | ||
| P/OCF | 14.01 | ||
| P/B | 1.02 | ||
| P/tB | 1.19 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.88%
EPS(NY)10.25
Fwd EY4.01%
FCF(TTM)12.48
FCFY4.89%
OCF(TTM)18.22
OCFY7.14%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)7.72
PEG (5Y)N/A
Graham Number236.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.12 |
F-Score5
WACC10.47%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y3.33%
EPS Next 2Y7.08%
EPS Next 3Y-3.38%
EPS Next 5Y-2.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.85%
Revenue Next Year1.61%
Revenue Next 2Y2.36%
Revenue Next 3Y2.35%
Revenue Next 5Y1.6%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 3.33% in the next year.